AbbVie to Present at the Wolfe Research Healthcare Conference
Get Alerts ABBV Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.6%
EPS Growth %: +107.5%
Join SI Premium – FREE
NORTH CHICAGO, Ill., Nov. 9, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 4th Annual Wolfe Research Healthcare Conference on Tuesday, November 15, 2022. Rob Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, commercial operations, Scott Reents, senior vice president and chief financial officer, and Neil Gallagher, vice president development and chief medical officer will present virtually at 10:30 a.m. Central time.
A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, and women's health, in addition to products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
View original content:https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-wolfe-research-healthcare-conference-301672371.html
SOURCE AbbVie
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Capital Group secures FSRA licence in Abu Dhabi as it expands in the Middle East
- Daniel DeCapua, Realtor in Ann Arbor, MI, Says After 2,000 Career Sales That Another Price Cut Is Not Always the Answer
- Form 8.5 (EPT/RI)-Advanced Medical Solutions Group plc
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share